Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amlodipine
Drug ID BADD_D00121
Description Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers [A175327]. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure [A175321]. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label].
Indications and Usage For the treatment of hypertension and chronic stable angina.
Marketing Status Prescription; Discontinued
ATC Code C08CA01
DrugBank ID DB00381
KEGG ID D07450
MeSH ID D017311
PubChem ID 2162
TTD Drug ID D08JIV
NDC Product Code 52652-5001; 46287-035
Synonyms Amlodipine | Amlodipine, (+-)-Isomer | Amlodipine Besylate | Amlodipine, (+-)-Isomer, Maleate (1:1) | Amlodipine, (S)-Isomer, Maleate (1:1) | Amlodis | Astudal | Norvasc | Istin | Amlor | Amlodipine Maleate | Amlodipine Maleate (1:1) | Amlodipine, (R)-Isomer
Chemical Information
Molecular Formula C20H25ClN2O5
CAS Registry Number 88150-42-9
SMILES CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Suicidal ideation19.12.01.003--
Suicide attempt19.12.01.0040.000476%
Swelling08.01.03.0150.000430%Not Available
Swelling face23.04.01.018; 10.01.05.018--Not Available
Swollen tongue10.01.05.015; 07.14.02.003; 23.04.01.0140.000077%Not Available
Syncope02.01.02.008; 24.06.02.012; 17.02.04.0080.000215%
Tachycardia02.03.02.0070.000368%Not Available
Tachypnoea22.02.01.0140.000046%Not Available
Tension19.06.02.005--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Throat irritation22.02.05.013; 07.05.03.0040.000061%Not Available
Throat tightness22.02.05.015; 19.01.02.0050.000031%Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombosis24.01.01.006--Not Available
Thyroid disorder05.02.01.0020.000031%Not Available
Tinnitus04.04.01.002; 17.04.07.0040.000077%
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.0070.000061%Not Available
Tooth loss07.09.09.0010.000046%Not Available
Torticollis17.01.03.003; 15.05.04.0030.000031%Not Available
Toxic encephalopathy12.03.01.027; 17.13.01.0040.000031%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.000008%
Transient ischaemic attack24.04.06.005; 17.08.04.0010.000138%
Tremor17.01.06.0020.000184%
Unresponsive to stimuli17.02.05.0310.000077%Not Available
Upper gastrointestinal haemorrhage24.07.02.024; 07.12.02.0060.000012%
Urethral disorder20.07.01.002--Not Available
Urinary retention20.02.02.0110.000138%
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.0010.000292%
Vascular purpura23.06.01.008; 01.01.04.007; 24.07.06.011--Not Available
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 17 Pages